Immunotherapy targeting tumor‐associated antigen in a mouse model of head and neck cancer

Documenti analoghi

• Differences in PD‐L1, PD‐L2, and EGFR Expression Between Naive and Recurrent Tumors in Patients With Head and Neck Squamous Cell Carcinoma: A Retrospective Study
  di: Ryosuke Sato, et al.
  Pubblicazione: (2025)
• Combined approach for predicting the efficacy of nivolumab in head and neck carcinoma by tissue and soluble expressions of PD‐L1 and PD‐L2
  di: Ryosuke Sato, et al.
  Pubblicazione: (2024)
• Soluble CD27 as a predictive biomarker for intra‐tumoral CD70/CD27 interaction in nasopharyngeal carcinoma
  di: Toshihiro Nagato, et al.
  Pubblicazione: (2024)
• Prognostic Value of the 18 F ‐ FDG PET / CT and Haematological Parameters in Head and Neck Cancer
  di: Risa Wakisaka, et al.
  Pubblicazione: (2024)
• Objective response rate predicts survival in recurrent or metastatic head and neck squamous cell carcinoma treated with immune checkpoint blockade but not with targeted therapy: A retrospective multicenter study
  di: Takahiro Inoue, et al.
  Pubblicazione: (2026)